Clinical Trial

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-12-01; most recent amendment 2024-11-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-02-01
Trial Details
NCT Number NCT05636436
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions Herpes Zoster
Enrollment 132 participants
Start Date 2022-12-07
Primary Completion 2024-12-30 (estimated)
Study Completion 2024-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-20